For Investors
2017 was an important year of transition for RepliCel shareholders. The company delivered its first complete set of phase 1 human clinical data, the first fully functional prototypes of its dermal injector, and a second major international co-development and licensing partnership in Asia.
2018 is expected to deliver more partnership announcements, the launch of next phase clinical trials, and see RepliCel transition into steady revenue generation as the company prepares for the first the commercial launch of one of its products.
Here you can keep up-to-date with our share price, upcoming events, and latest presentations. We invite you to sign up for our email alerts and welcome any questions you may have.
| RP.V | |
|---|---|
| Last | N/A |
| Change | N/A |
| Change % | N/A |
| Open | N/A |
| 52 Week Low | N/A |
| 52 Week High | N/A |
| Volume | N/A |
- 1 mo
- 3 mo
- 6 mo
- 1 yr
- 2 yr
- 5 yr
REPCF Market Data
| Corporate Name
|
RepliCel Life Sciences. |
| Exchange/Symbol | OTCQB/REPCF |
| Exchange/Symbol | TSXV/RP |
| Shares Issued
|
26,800,484 |
| Shares Issued on a Fully Diluted Basis | 33,393,036 |
| Insider Ownership | 21% |
| CUSIP # | 76027P103 |
| ISIN # | CA 76027P1036 |
| Fiscal Year End | December 31 |
| Date of Incorporation | 1967 |
| Incorporated | British Columbia, Canada |
| Industry | Life Sciences |
| Transfer Agent | Computershare |
| Corporate Attorneys | Clark Wilson LLP |
| Auditors | BDO Canada LLP |